NYXH Nyxoah SA

Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company.

Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 […]

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

Nyxoah SA (NYXH) shares jumped 15% in Wednesday trading after it said its ACCCESS US pivotal study m

Nyxoah SA (NYXH) reports strong US commercial momentum with active accounts doubling to 180, while securing capital to accelerate its launch ramp.

Nyxoah (NASDAQ:NYXH) reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequen

Nyxoah (NASDAQ:NYXH) used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability. Chief Executive Officer Olivier Taelman said there is “a lot of excitement in

Nyxoah’s latest analyst update includes a reduced fair value estimate, moving from €7.37 to €5.80, a cut of roughly 21% in the refreshed model. Street research links this lower price target to a mix of optimism around Genio’s product uptake, as well as caution around funding needs, execution risk and the recent capital raise. Read on to see how these shifting assumptions are reshaping the Nyxoah story and how you can keep track as the narrative evolves. Analyst Price Targets don't always...